Filtered By:
Condition: Pulmonary Hypertension
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 621 results found since Jan 2013.
Sickle Cell Trait and Risks for Common Diseases: Evidence from the UK Biobank
Sickle cell disease is an autosomal recessive disease caused by the inheritance of two pathogenic mutations of the hemoglobin subunit beta gene (HBB) (usually Glu6Val, though other pathogenic mutations exist).1 The altered hemoglobin makes red blood cells prone to being crescent-shaped, which can cause vaso-occlusion and result in numerous serious complications and comorbidities including: vaso-occlusive crisis, acute chest syndrome, infections, pulmonary hypertension, stroke, pulmonary embolism, renal failure, retinopathy, splenic sequestration, priapism, cholelithiasis, and osteonecrosis.
Source: The American Journal of Medicine - April 21, 2022 Category: General Medicine Authors: Joseph Hulsizer, W. Kyle Resurreccion, Zhuqing Shi, Jun Wei, Skylar Ladson-Gary, S. Lilly Zheng, Brian T. Helfand, Liana Billings, Michael S. Caplan, Jianfeng Xu Source Type: research
The Cardiovascular and Metabolic Effects of Chronic Hypoxia in Animal Models: A Mini-Review
Front Physiol. 2022 Mar 31;13:873522. doi: 10.3389/fphys.2022.873522. eCollection 2022.ABSTRACTAnimal models are useful to understand the myriad physiological effects of hypoxia. Such models attempt to recapitulate the hypoxemia of human disease in various ways. In this mini-review, we consider the various animal models which have been deployed to understand the effects of chronic hypoxia on pulmonary and systemic blood pressure, glucose and lipid metabolism, atherosclerosis, and stroke. Chronic sustained hypoxia (CSH)-a model of chronic lung or heart diseases in which hypoxemia may be longstanding and persistent, or of hi...
Source: Atherosclerosis - April 18, 2022 Category: Cardiology Authors: Laura A Barnes Omar A Mesarwi Ana Sanchez-Azofra Source Type: research
Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Reservoir Pressure Analysis in Group 2 Pulmonary Hypertension
In this study we aim to describe Pres in Group 2 isolated post-capillary (IPC) and combined pre and post-capillary (CPC) pulmonary hypertension (PH).
Source: The Journal of Heart and Lung Transplantation - April 1, 2022 Category: Transplant Surgery Authors: I. Yim, K. Parker, S. Lim Tags: (307) Source Type: research
New Janssen Initiative Aims to Advance Equitable Care and Address Hidden Threat of Amputation Related to Peripheral Artery Disease (PAD)
TITUSVILLE, N.J., March 31, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the launch of Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now, a multi-year initiative aimed at creating urgency and action to address the hidden threat of peripheral artery disease (PAD)-related amputation, with an initial focus on reaching Black Americans, who are more than twice as likely to be impacted by PAD.1 Janssen has joined forces with leading professional associations, healthcare systems and community organizations to advance equitable care for individuals and communities placed at an...
Source: Johnson and Johnson - March 31, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
The Cardiovascular and Metabolic Effects of Chronic Hypoxia in Animal Models: A Mini-Review
Animal models are useful to understand the myriad physiological effects of hypoxia. Such models attempt to recapitulate the hypoxemia of human disease in various ways. In this mini-review, we consider the various animal models which have been deployed to understand the effects of chronic hypoxia on pulmonary and systemic blood pressure, glucose and lipid metabolism, atherosclerosis, and stroke. Chronic sustained hypoxia (CSH)—a model of chronic lung or heart diseases in which hypoxemia may be longstanding and persistent, or of high altitude, in which effective atmospheric oxygen concentration is low—reliably induces pu...
Source: Frontiers in Physiology - March 31, 2022 Category: Physiology Source Type: research
Exosomes and the cardiovascular system: role in cardiovascular health and disease
This article is protected by copyright. All rights reserved.PMID:35306667 | DOI:10.1113/JP282054
Source: The Journal of Physiology - March 20, 2022 Category: Physiology Authors: Karla B Neves Francisco J Rios Javier Sevilla-Montero Augusto C Montezano Rhian M Touyz Source Type: research
Association of autosomal dominant polycystic kidney disease with cardiovascular disease: a US-National Inpatient Perspective
ConclusionsThe prevalence of CVD is high among patients with ADPKD, and the most important risk factor associated with CVD is severity of RD. We found an increase in the trend of hospitalizations of patients with ADPKD associated with increased risk of AF, PHN, NICM, and hemorrhagic stroke. History of CVD is the strongest predictor of mortality among patients with ADPKD.
Source: Clinical and Experimental Nephrology - February 25, 2022 Category: Urology & Nephrology Source Type: research
A Novel Factor in Determining the Risk of Ischemic Cerebrovascular Events in Patients with Atrial Fibrillation: Pulmonary Hypertension
Pulmonary hypertension (PH) is closely related to clinical decompensation and poor clinical outcomes in atrial fibrillation (AF) patients. However, the association between PH and ischemic cerebrovascular events (ICE) in AF patients has not been investigated. The authors purposed to examine this relationship.
Source: Journal of Stroke and Cerebrovascular Diseases - February 16, 2022 Category: Neurology Authors: Serhat Karadavut, Murat Cetin Source Type: research
New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Impact of thyroid disease in patients with atrial fibrillation: Analysis from the JoFib registry
CONCLUSION: Despite having similar stroke and bleeding risks, patients with thyroid disease demonstrated meaningful differences in their baseline characteristics. Prospective studies are required to assess the influence of thyroid hormone fluctuations on the progression of AF.PMID:35145683 | PMC:PMC8818533 | DOI:10.1016/j.amsu.2022.103325
Source: Annals of Medicine - February 11, 2022 Category: Internal Medicine Authors: Hanna Al-Makhamreh Abdallah Al-Ani Dana Alkhulaifat Liza Shaban Neveen Salah Rusul Almarayaty Yazan Al-Huneidy Ayman Hammoudeh Source Type: research
